Food and Drug Administration
June 2, 2004
Briefing Document for Oxypurinol Capsules, NDA 21-740, Cardiome Pharma Corp. (PDF)
FDA Cover Letter, Dr. Brian Harvey, MD, PhD (HTM) (PDF) (Word)
NDA 21-740 Oxyprim™ - Preliminary Summary, FDA (HTM) (PDF) (Word)
FDA Bibliography (HTM) (PDF) (Word)
Clinical Trial Design and Endpoints for Drugs Intended to Treat Gout, TAP Pharmaceutical Products, Inc. (PDF)
Bibliography, TAP Pharmaceutical Products, Inc. (PDF)